ONCY Company Profile and Key Details

ONCY has shown mixed momentum, losing -0.1% over the past week and -16.05% over the past quarter, though year-to-date performance is up 13.34%. Short-term trend indicators are mixed aligned (SMA20 11.2%, SMA50 7.7%, SMA200 8.91%). The stock’s 14-day RSI is 54.88 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.14% below its high and over 228.42% above its low. Average 10-day trading volume of 1.42 million shares is slightly above the 3-month average of 1.27 million, indicating heightened recent market interest.

Oncolytics Biotech Inc. has 100.36 million shares outstanding. The public float is 98.78 million shares, elevated short interest at 2.61% of float. This equals 2.44 million shares. The short ratio is 1.72 days. Institutional investors hold 1.74% of the float. Insiders own 3.61%. Seizinger Bernd R. holds 566.99 thousand shares, Pisano Wayne has 492.41 thousand shares and Look Kirk has 287.52 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Oncolytics Biotech Inc. generated EPS of -$0.28 over the past year. Five-year average earnings growth is 23.13%. Wall Street analysts project EPS growth of 7.12% annually over the next five years. The latest quarter delivered EPS of -$0.10. The next quarter is forecast at -$0.06. Next year's EPS is expected at -$8.92. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $3.00. The high target offers 784.96% upside. The low target suggests 165.49% downside. The mean target is $6.00. This offers 430.97% upside. Oncolytics Biotech Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -16.67%. The prior quarter beat by -54.55%. Over the last six quarters, Apple has recorded several small beats. These include -12.5% in August 01, 2024.

Oncolytics Biotech Inc. (NASDAQ:ONCY) closed at $1.13 USD, gaining $0.06 (5.61%) from the previous close of $1.07. The stock is currently mid-range between its 52-week high and low $0.33 and $1.51. With a market capitalization of about $113.41 million, Oncolytics Biotech Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.95). Key stats such as the average daily volume over the past year has been around 1.27 million shares, in line with its 52-week average. Headquartered in Calgary, AB, Oncolytics Biotech Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jared Kelly, the company employs approximately 28 people and listed since October 05, 2001. Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.

Our AI price prediction model suggests that Oncolytics Biotech Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.65%, with price expected at $1.10 by March 13, 2026, within a range of $0.95 to $1.23 3-Month Outlook: Projected fall of -48.67%, reaching $0.58 by May 28, 2026, with a range of $0.54 to $0.63. 1-Year Outlook: Projected gain of 1297.35%, with price at $15.79 by February 26, 2027, within a range of $12.78 to $21.04.

Oncolytics Biotech Inc. (NASDAQ:ONCY) shares are up 13.34% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Oncolytics Biotech Inc. trading at a premium to the broader market with a P/E of -4.27. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.10, suggesting 616.81% upside. Our AI forecast model points to short-term weakness (-2.65% over two weeks), a medium-term fall (-48.67% over three months), and a longer-term gain (1297.35% over one year), with expected trading ranges indicating moderate volatility.

Oncolytics Biotech Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.14. This means the shares are trading above this model’s fair value.

Oncolytics Biotech Inc. trades at a P/E ratio of -4.27, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1308.95 reflecting a rich premium to book value. The P/FCF stands at -5.63, also below market averages. Compared to sector medians, Oncolytics Biotech Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.